Skip to main navigation

Live - Top Menu

  • Clinical Trials
  • Investors & Media
  • Careers
  • Contact Us
Menu
Close

Main navigation

  • Our Focus
  • Our Research
  • Our Medicine
  • Our Story
Home > Investors & Media > Press Releases
  • Investors & Media
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Leadership
      • Board of Directors
    • Financial Information
      • SEC Filings
    • Stock Information
      • Historic Stock Lookup
      • Investment Calculator
      • Dividend History
      • Analyst Coverage
    • Contact Us

Shareholder Tools

  • Email Alerts
  • Download Library
  • RSS
  • Print
  • Share
  • Facebook
  • LinkedIn
  • Twitter

Press Releases

Press Releases

Jan 11, 2021
Intercept Appoints Jared M. Freedberg as General Counsel and Secretary
NEW YORK , Jan. 11, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the appointment of Jared M.
Read More
Jan 05, 2021
Intercept to Present at the 39th Annual J.P. Morgan Healthcare Conference
NEW YORK , Jan. 05, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso , President and Chief
Read More
Dec 10, 2020
Intercept Pharmaceuticals Announces Leadership Transition
Jerry Durso Appointed CEO Effective January 1, 2021 ; Founder, President and CEO Mark Pruzansk i to Continue as Board Member   and Advis o r NEW YORK , Dec. 10, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and
Read More
Nov 24, 2020
Intercept to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
NEW YORK , Nov. 24, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Mark Pruzanski , M.D., President and
Read More
Nov 16, 2020
New Data from the Interim Analysis of REGENERATE Show OCA Improved Noninvasive Measures of Fibrosis in a Subgroup of High-Risk Patients with Fibrosis Due to NASH
Multiple new analyses reinforce the clinical value of noninvasive strategies to identify and monitor patients with advanced fibrosis due to NASH NEW YORK , Nov. 16, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and
Read More
Nov 09, 2020
Intercept Pharmaceuticals Reports Third Quarter 2020 Financial Results, Announces Updates to Financial Guidance and Provides Business Update
Worldwide Ocaliva net sales of $79.5 million in the third quarter 2020, representing 29% growth over the prior year quarter Intercept updates 2020 Ocaliva Net Sales Guidance to narrow the range to $310 million to $320 million Intercept updates 2020 non-GAAP Adjusted Operating Expenses Guidance to
Read More
Nov 02, 2020
Intercept to Announce Third Quarter 2020 Financial Results on November 9, 2020
NEW YORK , Nov. 02, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its third quarter 2020 financial results prior
Read More
Oct 29, 2020
New PBC and NASH Data to be Presented at AASLD’s The Liver Meeting Digital Experience™
Presentation of l ong -term   efficacy and   safety data of obeticholic acid (OCA )   for the treatment of patients with PBC A nalys i s from Phase 3 REGENERATE study examines the antifibrotic efficacy of   OCA on noninvasive measures of liver fibrosis   in patients with fibrosis due to NASH NEW
Read More
Sep 03, 2020
Intercept to Present at September Investor Conference
NEW YORK , Sept. 03, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Mark Pruzanski , M.D., President and
Read More
Aug 27, 2020
New Data from the Interim Analysis of REGENERATE Show that OCA Helped Patients with Liver Fibrosis Due to NASH Achieve Sustained Improvement in Noninvasive Markers of Fibrosis Over Two Years of Treatment
NEW YORK , Aug. 27, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced additional data indicating that obeticholic
Read More

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • …
  • Next page next ›
  • Last page last »
  • Investors & Media
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Leadership
      • Board of Directors
    • Financial Information
      • SEC Filings
    • Stock Information
      • Historic Stock Lookup
      • Investment Calculator
      • Dividend History
      • Analyst Coverage
    • Contact Us

Shareholder Tools

  • Email Alerts
  • Download Library
  • RSS
  • Print
  • Share
  • Facebook
  • LinkedIn
  • Twitter

Live - Footer Menu

  • Privacy Policy
  • Privacy Shield Policy
  • Corporate Compliance
  • Terms of Use
  • Contact Us
  • Cookie Preferences
10 Hudson Yards, 37th Floor|New York, NY 10001|T: 844-782-ICPT
© 2020 Intercept Pharmaceuticals, Inc.